The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events.  

In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of special reports and key insights from their interviews with multiple experts.  

To learn more about the topics in this episode: 
Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to immunology
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology
Biotech faces a reckoning: 'We've lost our luster in cell therapies'
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)

The Fierce Biotech team published a four-part series this week exploring cell therapy, a modality that has faced clinical challenges, manufacturing constraints and multiple practice-changing events.  
In today’s episode, Fierce’s Annalee Armstrong and Gabrielle Masson discuss the series of special reports and key insights from their interviews with multiple experts.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/research/how-remarkable-resolution-lupus-carried-car-t-cancer-immunology" data-cke-saved-href="https://www.fiercebiotech.com/research/how-remarkable-resolution-lupus-carried-car-t-cancer-immunology">Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to immunology</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/cell-therapy-reckoning-pivot-autoimmune-leaves-unmet-need-oncology" data-cke-saved-href="https://www.fiercebiotech.com/biotech/cell-therapy-reckoning-pivot-autoimmune-leaves-unmet-need-oncology">Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/biotech-faces-reckoning-weve-lost-our-luster-cell-therapies" data-cke-saved-href="https://www.fiercebiotech.com/biotech/biotech-faces-reckoning-weve-lost-our-luster-cell-therapies">Biotech faces a reckoning: 'We've lost our luster in cell therapies'</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/fulfilling-promise-cell-gene-therapies-through-manufacturing-part-i" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/fulfilling-promise-cell-gene-therapies-through-manufacturing-part-i">Fulfilling the promise of cell &amp; gene therapies through manufacturing (Part I)</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/cell-collection-commercial-contracting-advancements-cell-gene-therapy-manufacturing" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/cell-collection-commercial-contracting-advancements-cell-gene-therapy-manufacturing">From cell collection to commercial contracting: Advancements in cell &amp; gene therapy manufacturing (Part II)</a></li>
<li><a href="https://www.fiercepharma.com/manufacturing/automation-decentralization-and-future-car-ts-advancements-cell-gene-therapy" data-cke-saved-href="https://www.fiercepharma.com/manufacturing/automation-decentralization-and-future-car-ts-advancements-cell-gene-therapy">Automation, decentralization and the future of CAR-Ts: Advancements in cell &amp; gene therapy manufacturing (Part III)</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement